Dr. Patricia Muller

Programme Leader

Headshot of Dr Patricia Muller

MRC Toxicology Unit
Hodgkin Building
PO Box 138
University of Leicester
Lancaster Road, Leicester

Email: pm292@le.ac.uk

Qualifications and Personal History

2013-present, Programme track leader, MRC toxicology Unit, Leicester, UK

2013-present, Sir Henry Dale fellow sponsored by the Royal Society and the Welcome Trust

2014, Early Career Award from the Biochemical Society

2008-2013 Postdoc, Vousden group, The Beatson institute for Cancer Research, Glasgow, UK

2009-2011 Rubicon fellowship, sponsored by NWO, the Netherlands

2003-2008 PhD, Metabolic and Endocrine diseases department, UMC Utrecht, the Netherlands

1998-2003  MSc Medical Biology, University of Utrecht, the Netherlands

Selected Publications

    1. Muller PA, Vousden KH Mutant p53 in Cancer: New Functions and Therapeutic Opportunities. Cancer Cell 2014 Mar 17;25(3):304-317
    2. Muller PA, Trinidad AG, Caswell PT, Norman JC, Vousden KH Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype. J Biol Chem 2014 Jan 3;289(1):122-32
    3. Tan E.H., Morton JP, Timpson P, Tucci P, Melino G, Flores ER, Sansom OJ, Vousden KH, Muller PA Functions of TAp63 and p53 in restraining the development of metastatic cancer. Oncogene. 2013 Jul 22. [Epub ahead of print]
    4. Trinidad AG, Muller PA, Cuellar J, Klejnot M, Valpuesta JM, Vousden KH. Interaction with the CCT complex promotes protein folding and WT p53 activity. Mol Cell. 2013 Jun 27;50(6):805-17
    5. Muller PA, Trinidad AG, Caswell P, Noll JE, Coffill CR, Lane DP, Neilsen PM, Norman JC, Vousden KH Mutant p53 induces Met recycling and signalling to drive cell scattering and invasion. Oncogene. 2013 Mar 7;32(10):1252-65
    6. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013 Jan;15(1):2-8 review
    7. Tucci P,  Markert K,  Grespi F, Agostini M, Sayan B,  Vousden KH, Muller PA,Lowe S, Knight RA, Levine AJ, Melino G Loss of p63 and its miR-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15312-7
    8. Muller PA*, Coffill CR*,  Hogue KA,Cheok CF, Oh HK, Neo SP, Vousden KH, Lane DP, Blackstock WP, Gunaratne HJ. p53 interactome reveals Nardilysin as a p53R273H-specific binding  partner involved in invasion. (* shared first author) EMBO Rep. 2012 Jun 29;13(7):638-44
    9. Rainero E, Caswell PT, Muller PA, van Blitterswijk WJ, McCaffrey MW, Vousden KH, Graziani A,  Norman JC Diacylglycerol kinase-α controls RCP-dependent integrin trafficking to promote invasive migration. J Cell Biol. 2012 Jan 23;196(2):277-95.
    10. Muller PA, Vousden KH, Norman JC The emerging role of p53 and its mutants in tumour cell migration and invasion. J Cell Biol. 2011 Jan 24;192(2):209-18 Review
    11. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC, Vousden KH. Mutant p53 drives invasion by promoting integrin recycling. Cell. 2009 Dec 24;139(7):1327-41

Latest News